Display options
Cite
Nakagawa T. Strategies for developing novel therapeutics for sensorineural hearing loss. Front Pharmacol. 2014;5:206doi: 10.3389/fphar.2014.00206.
Nakagawa, T. (2014). Strategies for developing novel therapeutics for sensorineural hearing loss. Frontiers in pharmacology, 5206. https://doi.org/10.3389/fphar.2014.00206
Nakagawa, Takayuki. "Strategies for developing novel therapeutics for sensorineural hearing loss." Frontiers in pharmacology vol. 5 (2014): 206. doi: https://doi.org/10.3389/fphar.2014.00206
Nakagawa T. Strategies for developing novel therapeutics for sensorineural hearing loss. Front Pharmacol. 2014 Sep 16;5:206. doi: 10.3389/fphar.2014.00206. eCollection 2014. PMID: 25278894; PMCID: PMC4165348.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2014 Sep 16;5:206. doi: 10.3389/fphar.2014.00206. eCollection 2014.

Strategies for developing novel therapeutics for sensorineural hearing loss.

Frontiers in pharmacology

Takayuki Nakagawa

Affiliations

  1. Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Kyoto University Kyoto, Japan.

PMID: 25278894 PMCID: PMC4165348 DOI: 10.3389/fphar.2014.00206

Abstract

Sensorineural hearing loss (SNHL) is a common disability in the world; however, at present, options for the pharmacological treatment of SNHL are very limited. Previous studies involving human temporal bone analyses have revealed that the degeneration of the cochlea is a common mechanism of SNHL. A major problem for the development of novel pharmacotherapy for SNHL has been the limited regeneration capacity in mammalian cochlear cells. However, recent progress in basic studies has led to several effective strategies for the induction of regeneration in the mammalian cochlea, in accordance with the stage of degeneration. In addition, recent advances in the identification of human deafness genes and their characterization in mouse models have elucidated cellular and/or molecular mechanisms of SNHL, which will contribute to clarify molecular targets of pharmacotherapy for treatment of SNHL.

Keywords: cochlea; dedifferentiation; regeneration; sensorineural hearing loss; stem cell; transdifferentiation

References

  1. Drug Discov Today Dis Models. 2013;10(1): - PubMed
  2. Nat Med. 2005 Mar;11(3):271-6 - PubMed
  3. Neuroreport. 2003 Sep 15;14(13):1677-81 - PubMed
  4. Otol Neurotol. 2007 Oct;28(7):976-81 - PubMed
  5. Hear Res. 2009 Mar;249(1-2):15-22 - PubMed
  6. Hear Res. 2011 Jul;277(1-2):4-19 - PubMed
  7. Annu Rev Physiol. 2011;73:311-34 - PubMed
  8. Neuroreport. 2005 Nov 28;16(17):1919-22 - PubMed
  9. Mol Ther. 2013 Jun;21(6):1142-50 - PubMed
  10. Nat Med. 2003 Oct;9(10):1293-9 - PubMed
  11. Nat Neurosci. 2000 Jun;3(6):580-6 - PubMed
  12. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):4084-8 - PubMed
  13. Nature. 2013 Aug 8;500(7461):217-21 - PubMed
  14. J Neurosci. 2011 May 25;31(21):7938-49 - PubMed
  15. BMC Neurosci. 2014 May 22;15:66 - PubMed
  16. J Neurotrauma. 2008 Jan;25(1):72-7 - PubMed
  17. J Mol Med (Berl). 2006 Jan;84(1):37-45 - PubMed
  18. Expert Opin Drug Deliv. 2013 May;10(5):639-50 - PubMed
  19. J Neurosci. 2000 Jan 1;20(1):43-50 - PubMed
  20. Annu Rev Neurosci. 2012;35:509-28 - PubMed
  21. Development. 1999 Apr;126(8):1581-90 - PubMed
  22. J Neurosci. 2009 Nov 11;29(45):14077-85 - PubMed
  23. Cell. 2010 May 14;141(4):704-16 - PubMed
  24. Mol Cell Neurosci. 2009 Dec;42(4):391-8 - PubMed
  25. Stem Cells Dev. 2014 Jun 1;23(11):1275-84 - PubMed
  26. Opt Express. 2011 Aug 1;19(16):15415-28 - PubMed
  27. Hum Mol Genet. 2011 Jan 1;20(1):28-39 - PubMed
  28. J Neurosci. 2013 Aug 21;33(34):13686-94 - PubMed
  29. BMC Med. 2010 Nov 25;8:76 - PubMed
  30. J Assoc Res Otolaryngol. 2007 Mar;8(1):18-31 - PubMed
  31. Neurosci Lett. 2014 Feb 7;560:7-11 - PubMed
  32. Int J Dev Biol. 2007;51(6-7):633-47 - PubMed
  33. Development. 2013 Mar;140(6):1196-206 - PubMed
  34. Neuron. 2012 Jul 26;75(2):283-93 - PubMed
  35. J Neurosci. 2010 Sep 15;30(37):12387-99 - PubMed
  36. Curr Biol. 2002 Jul 9;12(13):1106-11 - PubMed
  37. Neuroreport. 2007 Dec 3;18(18):1911-4 - PubMed
  38. Mol Cell Neurosci. 2013 Sep;56:29-38 - PubMed
  39. Neuroreport. 2008 Oct 29;19(16):1585-8 - PubMed
  40. Nanomedicine (Lond). 2013 Jul;8(7):1155-72 - PubMed
  41. Biomed Opt Express. 2013 Feb 1;4(2):230-40 - PubMed
  42. Ther Deliv. 2011 Jun;2(6):807-14 - PubMed
  43. Audiol Neurootol. 2013;18(5):335-43 - PubMed
  44. Otol Neurotol. 2013 Aug;34(6):995-1004 - PubMed
  45. Neuron. 2013 Jan 9;77(1):58-69 - PubMed
  46. Mol Neurobiol. 2013 Dec;48(3):647-54 - PubMed
  47. Nature. 2012 Oct 11;490(7419):278-82 - PubMed
  48. Cell Reprogram. 2013 Dec;15(6):514-9 - PubMed
  49. Otol Neurotol. 2014 Feb;35(2):e84-9 - PubMed
  50. Med Electron Microsc. 2000;33(2):51-6 - PubMed
  51. J Med Genet. 2013 Sep;50(9):627-34 - PubMed
  52. J Assoc Res Otolaryngol. 2011 Oct;12(5):605-16 - PubMed
  53. J Neurosci. 2003 Sep 17;23(24):8596-607 - PubMed
  54. Physiol Rev. 2014 Jul;94(3):951-86 - PubMed
  55. Acta Otolaryngol. 2007 Sep;127(9):938-42 - PubMed
  56. PLoS One. 2012;7(10):e48704 - PubMed
  57. PLoS One. 2012;7(10):e48544 - PubMed

Publication Types